Scarica l'app Stockscreener
15.63
1.76%
0.27
Pre-mercato:
15.59
-0.04
-0.26%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Trading Systems Reacting to (TNXP) Volatility - Stock Traders Daily
How rising interest rates impact Tonix Pharmaceuticals Holding Corp. stock2026 world cup usa national team quarterfinals playmakers low block defense expert forecast guide - ulpravda.ru
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 - The Manila Times
Fibromyalgia and migraine drug maker to share brain research in SF - Stock Titan
Tonix highlights pathway for potential single-dose, seasonal protection against Lyme Disease - Proactive financial news
Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen - MarketBeat
Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results - MSN
Aug Gainers: How Tonix Pharmaceuticals Holding Corp stock reacts to inflationary pressuresMarket Activity Recap & Weekly Watchlist for Hot Stocks - moha.gov.vn
Tonix prices 615,025 shares at $16.26 in registered direct offering - Yahoo Finance
Tonix Pharma announces $20 million registered direct offering - MSN
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals secures $20 million investment from Point72 By Investing.com - Investing.com Nigeria
Tonix Pharma advances TNX-4800 Lyme disease program - MSN
Tonix Pharma Announces $20 Million Registered Direct Offering - TipRanks
Form 424B5 Tonix Pharmaceuticals - StreetInsider
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug - Asianet Newsable
What's Going On With Tonix Pharma Stock Monday?Tonix Pharmaceuticals (NASDAQ:TNXP) - Benzinga
Tonix Pharmaceuticals (TNXP) Secures $20 Million Investment - GuruFocus
Tonix Pharmaceuticals (TNXP) Unveils Updates on Lyme Disease Tre - GuruFocus
Tonix Pharmaceuticals Prices $20 Million Registered Direct Offering - marketscreener.com
Tonix Pharmaceuticals shares fall 6.4% premarket after co prices stock and warrant offering - marketscreener.com
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention - Investing.com
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering - GlobeNewswire
Drugmaker behind new fibromyalgia drug raises $20M for pipeline - Stock Titan
Tonix Pharmaceuticals Announces Updates on TNX-4800 for Lyme Disease Prevention - TradingView — Track All Markets
Tonix Pharmaceuticals Advances TNX-4800 Development for Lyme Disease Prevention Planning Clinical Trials for Innovative Monoclonal Antibody Therapy - Quiver Quantitative
A single shot to prevent Lyme each year? Inside Tonix’s antibody plan - Stock Titan
Avoiding Lag: Real-Time Signals in (TNXP) Movement - Stock Traders Daily
TNXP (Tonix Pharmaceuticals Holding) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2025) - GuruFocus
Tonix licenses global rights to novel non-opioid neuropathic pain drug TNX-4900 - Proactive financial news
Noble Financial Has Positive Outlook of TNXP FY2025 Earnings - MarketBeat
Published on: 2025-12-22 01:46:59 - Улправда
Recap Report: How rising interest rates impact Tonix Pharmaceuticals Holding Corp. stockQuarterly Risk Review & Low Risk High Win Rate Picks - Улправда
How Tonix Pharmaceuticals Holding Corp. stock benefits from tech adoptionJuly 2025 Summary & Low Risk Growth Stock Ideas - DonanımHaber
How Tonix Pharmaceuticals Holding Corp. stock reacts to inflationary pressuresMarket Growth Report & Verified Momentum Stock Watchlist - DonanımHaber
How analysts rate Tonix Pharmaceuticals Holding Corp. stock today2025 Technical Overview & Free Community Consensus Stock Picks - DonanımHaber
Why Tonix Pharmaceuticals Holding Corp. stock is trending among retail tradersAnalyst Upgrade & Safe Entry Trade Reports - Улправда
Tonix licenses S1R antagonist from Rutgers University - BioWorld MedTech
Tonix Pharma secures rights to TNX-4900 for pain management - MSN
Tonix Pharmaceuticals licenses worldwide rights to non-opioid pain drug By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Secures Global Rights for Promising Pain Treatment - GuruFocus
Tonix Pharmaceuticals Licenses Non-Opioid Pain Medicine Candidate From Rutgers University - marketscreener.com
Tonix Pharma Secures Rights to TNX-4900 for Pain Management - TipRanks
Tonix Pharmaceuticals licenses worldwide rights to non-opioid pain drug - Investing.com
Tonix Pharmaceuticals Licenses TNX-4900 for Neuropathic Pain - TradingView — Track All Markets
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University - The Manila Times
Tonix Pharmaceuticals Licenses TNX-4900, a Non-Opioid Analgesic with Promising Efficacy and Safety Profile for Neuropathic Pain - Quiver Quantitative
Tonix Pharmaceuticals announces licensing TNX-4900 - marketscreener.com
Tonix Pharmaceuticals Holding Corp. Announces That It Licensed Exclusive Rights to Its Tnx-4900 Product Candidate for Chronic Neuropathic Pain from Rutgers University - marketscreener.com
[8-K] Tonix Pharmaceuticals Holding Corp. Reports Material Event | TNXP SEC FilingForm 8-K - Stock Titan
Tonix Pharmaceuticals Announces Licensing TNX-4900, a - GlobeNewswire
(TNXP) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Equities Analysts Offer Predictions for TNXP FY2025 Earnings - MarketBeat
Tonix Pharmaceuticals announces reverse stock split - MSN
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel Amid Key Commercialization Phase - citybuzz
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel - citybiz
Tonix Pharma Appoints New General Counsel - TipRanks
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):